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Background. Nephrotic syndrome (NS) represents the asso-
ciation of proteinuria, hypoalbuminemia, edema, and hyperlipi-
demia. Steroid-resistant nephrotic syndrome (SRNS) is defined
by primary resistance to standard steroid therapy. It remains
one of the most intractable causes for end-stage renal disease
(ESRD) in the first two decades of life. Sporadic mutations in
the Wilms’ tumor suppressor gene WT1 have been found to be
present in patients with SRNS in association with Wilms’ tu-
mor (WT) and urinary or genital malformations, as well as in
patients with isolated SRNS.
Methods. To further evaluate the incidence of WT1 muta-
tions in patients with NS we performed mutational analysis in
115 sporadic cases of SRNS and in 110 sporadic cases of steroid-
sensitive nephrotic syndrome (SSNS) as a control group. Sixty
out of 115 (52%) patients with sporadic SRNS were male, 55/115
(48%) were female. Sex genotype was verified by haplotype
analysis. Mutational analysis was performed by direct sequenc-
ing and by denaturing high-performance liquid chromatogra-
phy (DHPLC).
Results. Mutations in WT1 were found in 3/60 (5%) male (sex
genotype) cases and 5/55 (9%) female (sex genotype) cases of
sporadic SRNS, and 0/110 (0%) sporadic cases of SSNS. One out
of five female patients with mutations in WT1 developed a WT,
2/3 male patients presented with the association of urinary and
genital malformations, 1/3 male patients presented with sexual
reversal (female phenotype) and bilateral gonadoblastoma, and
4/5 female patients presented with isolated SRNS.
Conclusion. According to the data acquired in this study, pa-
tients presenting with a female phenotype and SRNS and male
patients presenting with genital abnormalities should especially
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be screened to take advantage of the important genetic infor-
mation on potential Wilms’ tumor risk and differential ther-
apy. This will also help to provide more data on the phenotype/
genotype correlation in this patient population.
Nephrotic syndrome (NS) is defined as the associa-
tion of proteinuria, hypoalbuminemia, edema, and hy-
perlipidemia. It constitutes one of the most common
diagnoses made in pediatric nephrology. About 80% of all
children with sporadic NS respond to steroid treatment.
For decades, NS has been separated into two broad cat-
egories based upon its response to standard steroid ther-
apy: steroid-sensitive nephrotic syndrome (SSNS) versus
steroid-resistant nephrotic syndrome (SRNS) [1, 2]. In
SRNS, about 75% of patients exhibit renal histology of fo-
cal segmental glomerulosclerosis (FSGS), and about 20%
exhibit renal histology of minimal change nephrotic syn-
drome (MCNS). In SSNS, renal histology reveals MCNS
in 80% and FSGS in 20% [3]. Positional cloning revealed
defects in four different genes as monogenic causes for
familial cases of SRNS. Mutations in NPHS1, encoding
nephrin (OMIM 602716) cause congenital nephrotic syn-
drome (CNS) of the Finnish type [4]. NPHS2 (podocin)
mutations (OMIM 604766) cause SRNS type 1 [5]. Mu-
tations in ACTN4 encoding a-actinin 4 (OMIM 604638)
have been identified as an autosomal-dominant cause of
SRNS [6]. An additional locus has been mapped to chro-
mosome 11q21-q22 for an autosomal-dominant form of
nephrotic syndrome (OMIM 603965) [7]. Gene identi-
fication underlines the importance of genetic factors in
the pathogenesis of NS. Through identification of these
three genes as causative for SRNS, their gene products,
nephrin, podocin, and a-actinin 4, were identified as im-
portant for the function of the glomerular podocyte [8].
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Furthermore, sporadic mutations in the tumor suppres-
sor gene WT1 have been found to be present in patients
with SRNS, providing the fifth genetic cause of NS [9–
11]. WT1 encodes a transcription factor of the zinc finger
family. Four different transcripts are produced by alter-
native splicing [12, 13]. WT1 was identified by positional
cloning aiming to identify the gene responsible for the
childhood cancer, Wilms’ tumor (WT) [14, 15]. Inten-
sive investigation afforded to WT1 has revealed the as-
sociation of WT1 mutations with Denys-Drash syndrome
(DDS) [16, 17] and the Frasier syndrome (FS) [18]. DDS
in 46, XY patients present as a triad of WT, XY pseudo-
hermaphroditism, and progressive glomerulopathy; 46,
XX patients present with WT and progressive glomeru-
lopathy, with absence of XY pseudohermaphroditism [9–
11, 19–22]. Incomplete forms of DDS have been de-
scribed, including 46, XY patients with isolated diffuse
mesangial sclerosis [10, 22–24]. FS has been described as
the association of complete XY gonadal dysgenesis, NS,
and the development of gonadoblastoma in 46, XY pa-
tients, and as isolated nephropathy in 46, XX patients [19,
21]. Patients with DDS show gomerulopathy character-
ized mostly by the histologic finding of diffuse mesan-
gial sclerosis (DMS); the predominant lesion in patients
with FS is FSGS. In DDS, the nephropathy occurs in in-
fancy and usually progresses to end stage renal disease
(ESRD) in less than three years, whereas in FS, it occurs
later and leads to ESRD in the second decade of life [9,
19]. The risk for the development of a WT seems to be
increased predominantly in DDS [19]. In patients with
genetic characteristics of FS, an association with WT has
also been described [23, 25, 26]. DDS and FS form an
overlapping spectrum of disease presentation. Patients
sharing the clinical and genetic characteristics of both dis-
orders have been described. Constitutional heterozygous
germline mutations of WT1 have been identified in most
of the patients with DDS and FS [22]. In patients with
DDS over 95% of the mutations are found as missense
mutations in exon 8 and 9 of the WT1 gene, encoding
for zinc finger 2 and 3 [10]. FS is associated with specific
splice site mutations in exon 9 [24]. Female patients with
mutations in WT1 mostly present with isolated nephropa-
thy or nephropathy in association with WT. However, 46,
XX patients with WT1 mutations with urinary and genital
malformations have been described [10]. To further eval-
uate the incidence of WT1 mutations in patients with NS,
we performed mutational analysis in 115 sporadic cases
of SRNS, and in 110 sporadic cases of SSNS as a control
group.
METHODS
Blood samples for mutational analysis, clinical data,
and informed consent (www.renalgenes.org) were ob-
tained from patients or their parents. Genomic DNA was
isolated directly from blood samples by standard meth-
ods [27]. Diagnoses of SRNS and SSNS were established
by a pediatric nephrologist according to published crite-
ria [1]. For clinical evaluation we used a standard ques-
tionnaire (www.renalgenes.org) as previously described
[28]. Characteristic features defining the clinical diagno-
sis were: age of onset of nephrotic syndrome, response
to steroid therapy, histology of the kidney biopsy, pro-
gression to ESRD, the recurrence of FSGS after renal
transplantation, and the association with extrarenal man-
ifestations. Standard steroid treatment and response to
steroid treatment, as well as response to cyclosporine
A (CyA) and cyclophosphamide (CP) therapy, were de-
fined according to the International Study of Kidney
Disease in Children (ISKDC) and Arbeitsgemeinschaft
fu¨r Pa¨diatrische Nephrologie (APN) guidelines [1, 2].
Patients were categorized steroid-sensitive if at least a
partial response to steroids was present. Patients turn-
ing steroid-resistant in a later stage of the disease were
considered as “steroid-sensitive” (SSNS) for this study.
Congenital nephrotic syndrome (CNS) was defined as the
presentation of NS within the first two months of life. Eth-
nic backgrounds of patients were central Europe, Turkey,
and India. Before performing mutational analysis in exon
6–9 of WT1, mutations in NPHS2 (podocin) were ex-
cluded. One hundred fifteen sporadic patients with SRNS
and 110 sporadic patients with SSNS were included in
the study. Sixty out of one hundred fifteen (52%) pa-
tients with SRNS were male (sex genotype), 55/115 (48%)
were female (sex genotype). The sex genotype of the pa-
tients was verified by performing polymerase chain reac-
tion (PCR) with markers DXS9902, GATA172D05, and
DYS390. Except for one patient (F1194), sex genotype
and sex phenotype were identical for all patients with
SRNS included in this study. Haplotype analysis was per-
formed on an ABI Prism 3100-Avant Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) as described
elsewhere [29]. The clinical data were as follows. Renal
biopsy results in patients with sporadic SRNS were: FSGS
73/115 (63%), MCNS 17/115 (15%), mesangioprolifera-
tive glomerulonephritis (MP) 3/115 (3%), diffuse mesan-
gial sclerosis (DMS) 3/115 (3%), membranoproliferative
glomerulonephritis (MPGN) 5/115 (4%), no data or no
biopsy performed 14/115 (12%). In 66 of 110 patients
with SSNS, no renal biopsy was performed. In the re-
maining 44 patients with SSNS, biopsy results were as
follows: FSGS 20/44 (45%), MCNS 17/44 (39%), MPGN
5/44 (11%), MP 2/44 (5%) (Table 1). The low number of
biopsies performed in SSNS is explained by the milder
course of SSNS. The median age of onset was 4.8 years
in the SRNS patients and 4.3 years in the SSNS patients
(Table 1). CNS was diagnosed in 5/115 (4%) patients with
SRNS. The median age of onset of NS for the SRNS pa-
tients was 5.0 after subtracting the CNS patients (Table 1).
Thirty-two of 115 (28%) of the SRNS patients progressed
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Table 1. Clinical and mutational analysis data in 115 SRNS patients and 110 SSNS patients
Number of Median age of Biopsy FSGS/ Median age at Male/female
Group patients onset years MCNS/other/ND % ESRD ESRD years relation
SRNS
WT1 mutation 8/115a 4.4b 7/0/0/1 3 (38%) 13.0 3/5
Absence of WT1 mutation 107/115c 4.9d 66/17/11/13 29 (27%) 11.0e 57/50
Total of SRNS patients 115f 4.8g 73/17/11/14 32 (28%) 11.2h 60/55
SSNS
WT1 mutation 0/110 NA NA NA NA NA
Absence of WT1 mutation 110/110 4.3 20/17/7/66 3 (3%) 14.9 NA
Total of SSNS patients 110 4.3 20/17/7/66 NA NA NA
Abbreviations are: SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome; CNS, congential nephrotic syndrome; FSGS, focal
segmental glomerulosclerosis; MCNS, minimal change nephrotic syndrome; ESRD, end-stage renal disease; ND, no data available; NA, not applicable.
aOne patient presented as CNS; bmedian was 4.5 after subtracting the CNS patient; c4 patients presented as CNS; dmedian was 5.0 after subtracting the 4 CNS
patients; emedian was 12.4 after subtracting 1 CNS patient; f5 patients presented as CNS; gmedian was 5.0 after subtracting the 5 CNS patients; hmedian was 12.5 after
subtracting the CNS patients with ESRD.
Table 2. Primer sequences used for mutational analysis
Exon Forward Reverse
6 CCATCATTCCCTCCT AGCCTGCAGTGAAG
GATTG AAGAGG
7 AAGACCTACGTGAAT GTGTGAGAGCCTGG
GTTCAC AAAAGG
8 CCTTTAATGAGATCCCC GGGGAAATGTGG
TTTTCC GGTGTTTCC
9 CCTCACTGTGCCCACA GCACTATTCCTTCTC
TTGT TCAACTGAG
to ESRD with a median age of 11.0 years (Table 1). Three
of 110 SSNS patients progressed to ESRD. Two of 60
(3%) male patients presented with genital or urinary mal-
formations, 1/60 (2%) male patients presented with sex-
ual reversal, and 0/55 (0%) of female patients presented
with genital or urinary malformations.
Mutational analysis of exons 6 and 7 of the WT1 gene
was performed by denaturing HPLC (DHPLC), mu-
tational analysis of exons 8 and 9 by direct sequenc-
ing of the forward strands. Primers are shown in Table
2. Known single nucleotide polymorphisms within the
primer sequence were avoided (http://genome.ucsc.edu/)
because known single nucleotide variants within the
primer sequence can suppress amplification of one of
the two alleles of the amplified product. PCR products
of exons 6 and 7 from the patients were pooled with
a control individual and subjected to analysis by DH-
PLC [30]. Melting profiles were determined according
to the manufacturer’s recommendations (Transgenomic,
Inc., Omaha, NE, USA). Column temperatures for DH-
PLC analysis were 60.9◦C, 61.9◦C, 62.9◦C for exon 6,
and 60.7◦C, 61.7◦C, 62.7◦C for exon 7. Direct sequencing
was performed for samples containing heteroduplex elu-
tion peaks. Sequencing was performed as previously de-
scribed [29]. Very high sequence quality was obtained. If
in doubt, the complementary strand was also sequenced.
To rule out polymorphisms, 160 chromosomes of healthy
control individuals were checked for novel mutations by
direct sequencing. For sequence evaluation the program
SequencherTM (GeneCode, Ann Arbor, MI, USA) was
used.
RESULTS
Types of WT1 mutations found
Mutational analysis of exons 6–9 of WT1 was per-
formed in 115 sporadic cases of SRNS and 110 patients
with SSNS. In 8/115 sporadic cases with SRNS and in none
of 110 sporadic SSNS cases were mutations detected in
exon 6–9 of WT1. Two different missense mutations and
6 splice site mutations were identified. These two mis-
sense mutations identified in exon 9 were novel (Table 3,
Fig. 1). Both novel mutations were absent in 160 chromo-
somes of healthy control individuals. They consisted of a
T1162C transition leading to a nonconservative amino
acid exchange C388R, found heterozygously in F1031. A
similar mutation C388Y affecting the same codon was
described before [31]. An A1190C transition leading to a
nonconservative amino acid exchange H397P was found
heterozygously in F734 (Fig. 1). The known splice site
mutation IVS9+4 G > A was found heterozygously in
F953, F999, and F1194. The known splice site mutation
IVS9+5 G > A was found in F921, F963, and F1073
(Table 3). Thirty patients with sporadic SRNS and mu-
tations in NPHS2 (podocin) [32] were also analyzed for
mutations in WT1. No mutation in exons 6–9 of WT1
could be identified in these patients. The 8 patients car-
rying mutations in WT1 were examined for mutations in
the 8 exons of NPHS2. In none of these patients was a
mutation in NPHS2 identified.
Clinical data
In 8 SRNS patients mutations in exons 6–9 of WT1 were
identified. Missense mutations in exon 8 and 9 are known
to be associated with DDS. Patients F1031 (C388R) and
F734 (H397P) with missense mutations in exon 9 pre-
sented with early onset of NS. Histology of the kidney
biopsy revealed FSGS in F734, no biopsy was performed
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Fig. 1. Detection of two novel WT1 mutations by direct sequencing
in F734 and F1031. The corresponding nucleotide sequences with the
encoded amino acids are shown above each chromatogram. The up-
per chromatograms show the novel heterozygous missense mutations
C388R (T1162C) (left) and H397P (A1190C) (right) in WT1. The lower
chromatograms show a healthy control individual.
in F1031 (Table 3). F1031 developed a unilateral WT
at the age of 1.5 years. As expected, genital or urinary
malformations were not described for any of the female
patients with a missense mutation in WT1.
Splice site mutations in exons 8 and 9 of WT1 are
known to be associated with FS. The onset of NS in the
6 patients with splice site mutations was later compared
to the patients with missense mutations with an average
of 5.3 years (range 2.3 to 8.9). Patients F921, F963, and
F999 progressed to ESRD with an average of 7.6 years
(range 5.8 to 11 years). These data are consistent with pre-
viously published data [9, 10]. Kidney biopsies showed
FSGS in all patients. Patient F999 and F921 received a
kidney transplant. No recurrence of FSGS in the trans-
plant was described. In the male patient F963, nephropa-
thy was associated with a bilateral testicular atrophy, in
the male patient F1073, the nephropathy was associated
with hypospadias. For all patients with SRNS the sexual
genotype was verified by haplotype analysis with mark-
ers DXS9902, GATA172D05, and DYS390. Patient F1194
with a female phenotype showed a XY karyotype, which
corresponds to a complete sexual reversal. After identi-
fying a splice site mutation in exon 9 and verifying the
karyotype in this patient, gonadectomy was performed.
Histology revealed a bilateral gonadoblastoma. No signs
of metastatic spread were present. This underlines the im-
portance of mutational analysis in these patients. Except
for F1194, sex genotype and sex phenotype were identi-
cal for all patients with SRNS included in this study. No
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genital or urinary malformations were described in the
female patients (Table 3).
DISCUSSION
Here we describe the results of the first screening for
mutations in exons 6–9 of WT1 in a large cohort of pa-
tients with SRNS. In 8/115 (7%) of sporadic SRNS cases
mutations in exons 6–9 of WT1 were identified altogether.
In two female patients, missense mutations in exon 9 con-
sistent with the diagnosis of DDS were identified; in one
of them WT was diagnosed. In three male and three
female patients, splice site mutations in exon 9 consis-
tent with the diagnosis of FS were found. Two of the
male patients presented with urinary or genital malfor-
mations, one of them with sexual reversal and bilateral go-
nadoblastoma. All three female patients presented with
isolated FSGS. No mutations were found in 110 sporadic
cases of SSNS, used as a control group. Our study gener-
ates the first data about the occurrence of WT1 mutations
in a large cohort of sporadic SRNS patients.
Two different clinical phenotypes associated with WT1
mutations and glomerulopathy have been described in
the literature. Missense mutations most commonly found
in exons 8 and 9 are associated with DDS, and specific
splice site mutations in exon 9 with FS. However, patients
with characteristic genetic findings of FS presenting with
clinical symptoms of DDS and vice versa were described
[10, 21, 23, 25, 26], suggesting that both diseases should be
considered as part of a spectrum of WT1 gene mutations
rather than as separate diseases.
Here we describe two novel missense mutations lead-
ing to amino acid exchanges C388R and H397P. Accord-
ing to the literature these findings are consistent with the
diagnosis of DDS [10]. The mutations were absent in the
parents of F1031 and the mother of F734, giving evidence
for a spontaneous mutation in both patients. Early onset
of NS was present in both patients as described previ-
ously for patients with DDS by others [9–11]. F1031 also
developed a unilateral WT. As both patients were female,
no genital or urinary malformations were described. In
contrast to the classic form of DDS, the renal histology of
patient F734 revealed FSGS. Other cases with missense
mutations and the diagnosis of FSGS have been described
before [9]. This further emphasizes the clinical overlap of
DDS and FS. The occurrence of the WT in F1031 under-
lines the importance of the WT1 screening in patients with
early onset NS. The finding of missense mutations in WT1
indicates an increased risk of WT; therefore, careful mon-
itoring of all patients with WT1 mutations is required.
After reaching ESRD, bilateral nephrectomy should be
performed to prevent the development of a WT.
In 6 patients splice site mutations in exon 9 were iden-
tified, consistent with the diagnosis of FS [24]. These mu-
tations impair the use of the second alternative splice
donor site. Normally, alternative splicing results either in
the inclusion or exclusion of the three amino acids lysine,
threonine, and serine (KTS) in a ratio of approximately
2:1 +KTS/−KTS isoforms. Splice site mutations in exon
9 lead to a reversal of this +KTS/−KTS isoform ratio to
1:2. The presence of both alternatively spliced isoforms
is crucial for normal kidney development. The reduction
of the +KTS levels lead to the development of glomeru-
losclerosis [33]. Typically, the onset of NS and the pro-
gression to ESRD was later in our patients presenting
with FS, compared with DDS. The renal histology was
FSGS in all patients. Second, the +KTS/−KTS isoforms
play an important role in male sexual differentiation by
regulating the Y chromosome–encoded Sry gene, which
initiates male sex determination in mammals. Mice lack-
ing the +KTS isoform were shown to have significantly
reduced Sry levels, and hence, explain the lack of the ini-
tiation of the male sex determination pathway in these
animals [33]. Nephropathy was associated with genital
and urinary malformations in the male patients, F1073
presented with hypospadias, and F963 with testicular at-
rophy and testicular microcalcification. In F1194 a 46, XY
karyotype with sexual reversal was found. Because of the
increased risk of gonadoblastoma, gonadectomy was per-
formed and bilateral gonadoblastoma without metastatic
spread was diagnosed, again emphasizing the importance
of the screening and of the verification of the karyotype.
46, XY patients with DDS present with a broad spec-
trum of intersex and hermaphrodite phenotypes; FS pa-
tients with a 46, XY karyotype can present with normal
female external genitalia, and those with a 46, XX kary-
otype appear to have normal gonadal development. As
shown in F1194, sex reversal in 46, XY patients is asso-
ciated with streak gonads and a high risk of gonadoblas-
toma; the karyotype should be examined in all female
patients carrying mutations in the splice site of exon 9.
In our study genital or urinary malformations were ab-
sent in 5 female patients with mutations in WT1. Patients
F963 and F1073, carrying a characteristic mutation for FS
only, show impairment of the genital and urinary devel-
opment but still present with male external genitalia. This
further underlines the complexity of the phenotypes seen
in patients with mutations in WT1. WT was diagnosed
in one patient with characteristic mutation for DDS as
compared to none of the patients with mutations charac-
teristic for FS. Previously, the absence of WT was con-
sidered as a characteristic feature of FS compared to the
high incidence of WT in DDS. Nevertheless, recently, FS
cases carrying the characteristic splice site mutation and
presenting with WT were reported [23, 25, 26]. Al-
though specific characteristics apply to FS and DDS,
many questions on the phenotype/genotype correlation
remain unanswered.
In the initially published studies of WT1 mutational
analysis, more patients associated with WT or urinary or
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genital malformations were included. This explains the
previously published male/female ratio of mutations in
WT1 of approximately 2:1 [9]. It was suggested that in
the past the correct diagnosis had been missed in female
patients because female patients in general may have less
severe or missing gonadal problems, when carrying muta-
tions in WT1 [9]. In the meantime, different studies have
been performed on mutational analysis in single cases, as
well as in smaller cohorts of isolated FSGS or isolated
DMS. Thereby, it was shown that mutations in WT1 show
a common cause of isolated FSGS in female patients [9–
11, 19]. Here we describe the first data on the prevalence
of mutations in a large cohort of patients with SRNS. We
identified mutations in exons 6–9 of WT1 in 5/55 (9%) fe-
male patients with sporadic SRNS and in 3/60 (5%) male
patients with sporadic SRNS. In contrast to the previously
published data, the incidence of mutations in female pa-
tients with isolated FSGS is surprisingly high. The lower
incidence of mutations in WT1 in male patients compared
to the female patients can be explained by the fact that
only 2/59 phenotypical male patients with urinary or gen-
ital malformations were included in this study.
CONCLUSION
The data provided in this study on mutational analysis
in 115 sporadic patients with SRNS emphasize the rele-
vance of mutational analysis of WT1 in this cohort. The
data generated here present clear evidence for the im-
portance of extending the screening of WT1 mutations
to all children with SRNS. In patients with WT1 muta-
tions, a renal ultrasound screening for the development
of tumors should be employed. According to the data ac-
quired in this study, especially patients presenting with
a female phenotype and SRNS, and male patients pre-
senting with genital abnormalities, should be screened. In
male and female patients with DDS there is a high risk for
the occurrence of WT. Therefore, close renal ultrasound
monitoring should be applied in all patients. When reach-
ing ESRD, nephrectomy should be performed to prevent
WT. In male patients with FS and sexual reversal, the inci-
dence for gonadoblastoma is increased; again, close ultra-
sound monitoring and gonadectomy should be performed
in these cases. Although the risk for WT is much lower
in FS than in DDS, the occurrence of WT should be still
considered in FS, as described for previously published
cases. In addition, future studies may relate the prognosis
on the outcome of kidney transplantation, as well as the
efficiency of immunosuppressive therapy to the presence
of WT1 mutations. For this reason, mutational analysis
should be extended to all children presenting with SRNS
to take advantage of the very important genetic informa-
tion when treating these children. This will also help to
provide more data on the phenotype/genotype correla-
tion in this patient population.
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